Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study.
Authors
Yongkang Xu
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Yongkang Xu , Shumin Fu , Ye Mao , Fengming Yi , Weiming Jiang , Long Feng , Jianbing Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
ChiCTR2200064384
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 500)
DOI
10.1200/JCO.2024.42.3_suppl.500
Abstract #
500
Poster Bd #
D7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with penpulimab and hepatic artery infusion chemotherapy (HAIC) in the first-line treatment of unresectable hepatocellular carcinoma.
First Author: Gong-Rang Chen
Poster
2021 ASCO Annual Meeting
A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study).
First Author: MinKe He
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line lenvatinib plus pembrolizumab plus chemotherapy versus chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma (LEAP-015): Safety run-in results.
First Author: Patricio Eduardo Yanez
Poster
2022 ASCO Annual Meeting
Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage c: A prospective, single-arm, phase II trial (TRIPLET study).
First Author: Yang-Kui Gu